Why AbbVie Could Join the M&A Mania Soon Post author:Sam Post published:January 30, 2018 Post category:BioPharma The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash. Source: BioSpace You Might Also Like Heptares Co-Founder Resigns as VP and CSO of Parent Company Sosei January 18, 2018 Troubled Cempra Slashes 67% of Workforce February 27, 2017 Anika Therapeutics To Issue Third-Quarter 2017 Financial Results And Business Highlights On Wednesday, October 25 October 11, 2017
Anika Therapeutics To Issue Third-Quarter 2017 Financial Results And Business Highlights On Wednesday, October 25 October 11, 2017